Company intelligence / Profile preview

Cibus

San Diego, California, United Statescibus.com ↗

Ownership: Public · CBUS
Employees: ~159
Development stage: Commercial

Overview

Cibus has developed a proprietary non-transgenic gene-editing platform enabling rapid development of crop productivity and sustainability traits. Three out of six key trait programs have entered customer transfer/commercialization phases in canola and rice. The company is advancing additional disease resistance and productivity trait programs with promising early results, including durable white mold resistance in canola.

Therapeutic areas: Other
Modalities: Gene editing technology (specifically non-transgenic gene editing; RTDS platform)
Industry: Agriculture & AgTech

Partnerships

Multiple seed companies as customers/licensees—11 different seed companies referenced as partners/licensees for edited germplasm/traits.

Financials

Market cap: $122.9M
Total revenue: $994K
Enterprise value: $135.2M

Beyond the preview

Go deeper on Cibus.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cibus.

Explore the full profile